secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K/A
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001683168-25-008512
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte acquires $3M convertible stake in Q/C Technologies; Q/C has going concern
--------------------------------------------------------------------------------

- PharmaCyte bought Q/C Series H convertible preferred shares and warrants for $3M, convertible into 600,000 common shares each.
- Q/C's auditors express substantial doubt about its ability to continue as a going concern due to net losses and negative cash flows.
- Pro forma combined financials reflect the transaction; Q/C's financial statements show recurring operating losses.
- Warrants expire five years after stockholder approval of issuance exceeding 19.99% of Q/C outstanding shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316825008512/0001683168-25-008512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316825008512/pharmacyte_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-008512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer